Docket Number 103576.166

Application Number (09/460,293

Applicant

Chen, Zhijian H.

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

OF Sheet 5

Filing Date September 24, 1999 Group Art Unit

- · 1652

U.S. Patent Documents —										
_		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
Foreign Patent Documents										
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO			
Other Documents (Industing Author Title Date Portinent Pages Ste.)										
M	A 1		n Vitro Stimulatio	n of IkB Phosphory	lation Is Not					
M	A2	Degradation via	the Ubiquitin-Pro							
	-A3	with Assembly o	f a Novel Type of							
(4)	A'4'				s of the Hun	nan Genome	and its			
	A 5	Auphan et al., "Immunosuppression by Glucocorticoids: Inhibition of NF-kB Activity Through Induction of IkB Synthesis" Science, Vol. 270, pp. 286-290 (1995)								
	A6	Baeuerle and Henkel, "Function and Activation of NF-kB in the Immune System" Annu. Rev. Immunol., Vol. 12, pp. 141-179 (1994)								
	A7					ed, Ubiquitin	-Mediated			
	A8				by Casein	Kinase II" Pi	oc. Natl. Acad.			
	A 9									
	A10	Belvin, et al., "Cactus Protein Degradation Mediates Drosophila Dorsal-Ventral Signaling" Genes and Dev., Vol. 9, pp. 783-793 (1995)								
\	A11	Blank, et al., "Molecular Cloning of Mitogen-activated Protein/ERK Kinase Kinases (MEKK) 2 and 3" J. Biol. Chem., Vol. 271, No. 10, pp. 5361-5368 (1996)								
	A12						Pathways for			
	A13	Science, Vol. 26	7, pp. 1485-1488	(1995)						
M	A14				Lysine in a	Targeted Sh	ort-Lived			
	EXA	A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 A13	EXAMINER INITIAL DOCUMENT NUMBER A1 Alkalay, et al., "I Mol. Cell. Biol., "Alkalay, et al., "Degradation via 10599-10603 (1) A2 Degradation via 10599-10603 (1) A3 Armason and Elli with Assembly of 7876-7883 (1994) A4 Expression" Sci. Auphan et al., "I Induction of IkB Baeuerle and He Immunol., Vol. 1 A6 Baldi, et al., "C Proteolysis of Ik Barroga et al., "C Proteolysis of Ik Barroga et al., "C Genes and Dev. A10 Belvin, et al., "C Genes and Dev. A11 Blank, et al., "Mand 3" J. Biol. C Genes and Dev. A12 Brockman, J.A., NF-kB Activation Brown, et al., "C Science, Vol. 26 A14 Chau, "A Multiut	Foreign EXAMINER INITIAL DOCUMENT DATE Other Doc Alkalay, et al., "In Vitro Stimulation Mol. Cell. Biol., Vol. 15, No. 3, pp Alkalay, et al., "Stimulation-Depe Degradation via the Ubiquitin-Pro 10599-10603 (1995) Arnason and Ellison, "Stress Resi with Assembly of a Novel Type of 7876-7883 (1994) Auffray, et al., "IMAGE: Integrated Expression" Sciences, Vol. 318, p. Auphan et al., "Immunosuppressi Induction of IkB Synthesis" Science Expression" Sciences, Vol. 218, p. Ab Baeuerle and Henkel, "Function a Immunol., Vol. 12, pp. 141-179 (1) Baldi, et al., "Critical Role for Lys Proteolysis of IkB-\alpha" Vol. 271, N. Barroga et al., "Constitutive Phos Sci., Vol. 92, pp. 7637-7641 (1999) Ab Beg, et al., "Turnor Necrosis Factor IkB-\alpha" and Belvin, et al., "Cactus Protein Degenes and Dev., Vol. 9, pp. 783-784 (1999) Blank, et al., "Molecular Cloning of and 3" J. Biol. Chem., Vol. 271, N. Brockman, J.A., "Coupling of a Si NF-kB Activation" Mol. Cell. Biol., Brown, et al., "Control of IkB-\alpha Pr. Science, Vol. 267, pp. 1485-1488 Chau, "A Multiubiquitin Chain is Control of IkB-\alpha Pr. Science, Vol. 267, pp. 1485-1488	Foreign Patent Documents Foreign Patent Documents EXAMINER INITIAL A1 DOCUMENT DATE Other Documents (Including Country) A1 Alkalay, et al., "In Vitro Stimulation of IkB Phosphory Mol. Cell. Biol., Vol. 15, No. 3, pp. 1294-1304 (1995) A2 Alkalay, et al., "Stimulation-Dependent IkB-α Phosp Degradation via the Ubiquitin-Proteasome Pathway" 10599-10603 (1995) A3 Amason and Ellison, "Stress Resistance in Saccharce with Assembly of a Novel Type of Multiubiquitin-Chair 7876-7883 (1994) A4 Auffray, et al., "IMAGE: Integrated Molecular Analysis Expression" Sciences, Vol. 318, pp. 263-272 (1995) A5 Auphan et al., "Immunosuppression by Glucocorticoi Induction of IkB Synthesis" Science, Vol. 270, pp. 28 A6 Baeuerle and Henkel, "Function and Activation of NF Immunol., Vol. 12, pp. 141-179 (1994) A8 Baldi, et al., "Critical Role for Lysines 21 and 22 in Sproteolysis of IkB-α "Vol. 271, No. 1, pp. 376-379 (1986) A8 Barroga et al., "Constitutive Phosphorylation of IkB-α Sci., Vol. 92, pp. 7637-7641 (1995) A9 Beg, et al., "Turmor Necrosis Factor and Interleukin-1 IkB-α: a Mechanism for NF-κB Activation." Mol. Cell. Biol., vol. 15, No. 5 (1995) A10 Blank, et al., "Molecular Cloning of Mitogen-activated and 3" J. Biol. Chem., Vol. 271, No. 10, pp. 5361-536 A11 Brockman, J.A., "Coupling of a Signal Response Dor NF-κB Activation" Mol. Cell. Biol., Vol. 15, No. 5 (1995) Brown, et al., "Control of IkB-α Proteolysis by Site-Sp. Science, Vol. 267, pp. 1485-1488 (1995) Chau "A Multiubiquitin Chain is Confined to Specific	Foreign Patent Documents Foreign Patent Documents EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS Other Documents (Including Author, Title Autho	Foreign Patent Documents Foreign Patent Documents Foreign Patent Documents Foreign Patent Documents CLASS SUBCLASS Other Documents (Including Author, Title, Date Perticular Processing Processi			

A /1 ////	DATE CONSIDERED
CHRONOLAN	5/10.6
EXAMINER: Initial in citation is considered, whether or not citati	
citation if not conformance and not considered. Include convivity	next communication to annicant

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

2

OF

5

Docket Number 103576.166 Application Number

09/460,293

Applicant

Chen, Zhijian H.

Filing Date

Group Art Unit

September 24, 1999

1652.

		81	Chen, et al., "Multiple Ubiquitin-Conjugating Enzymes Participate in the In Vivo Degradation of the Yeast MATα2 Repressor" Cell, Vol. 74, pp. 357-369 (1993)						
	7	B2	Chen, et al., "Signal-Induced Site-Specific Phosphorylation Targets IκB-α to the Ubiquitin-Proteasome Pathway" Genes and Dev., Vol. 9, pp. 1586-1597 (1995)						
1		B3	Chen, et al., "Site-Specific Phosphorylation of IκB-α by a Novel Ubiquitination-Dependent Protein Kinase Activity" Cell., Vol. 84 (1996) 853 - 862						
		84	Chen and Pickart, "A 25-Kilodalton Ubiquitin Carrier Protein (E2) Catalyzes Multi-ubiquitin Chain Synthesis via Lysine 48 of Ubiquitin" <i>J. Biol. Chem.</i> , Vol. 265, No. 35, pp. 21835-21842 (1990)						
F	T	85	Choi, et al., "Ste5 Tethers Multiple Protein Kinases in the MAP Kinase Cascade Required for Mating in S. cerevisiae" Cell, Vol. 78, pp. 499-512 (1994)						
ſ	T	86	Ciechanover. "The Ubiquitin-Proteasome Proteolytic Pathway" Cell, Vol. 79, pp.13-21 (1994)						
\int		87	Derijard, et al., "Independent Human MAP Kinase Signal Transduction Pathways Defined by MEK and MKK Isoforms" <i>Science</i> , Vol. 267, pp. 682-685 (1995)						
·		B8	-Derijard, et al., "JNK1: A Protein Kinase Stimulated by UV Light and Ha-Ras That Binds and—Phosphorylates the c-Jun Activation Domain" Cell, Vol. 76, pp. 1025-1037 (1994)						
1		B 9	Devary, et al., "NF-kB Activation by Ultraviolet Light Not Dependent on a Nuclear Signal" Science, Vol. 261, pp. 1442-1445 (1993)						
		B10	Diaz-Meco. "ZPKC Induces Phosphorylation and Inactivation of I kappa B-alpha In Vitro" EMBO J., Vol 13, No. 12, pp. 2842-2848 (1994)						
		B11	DiDonato, et al., "Phosphorylation of IkBa Precedes but IS Not Sufficient for Its Dissociation from NF-kB" Mol. cell. Biol., Vol. 15, No. 3, pp. 1302-1311 (1995)						
		B12	Dominguez, et al., "Inhibition of Protein Kinase C ζ Subspecies Blocks the Activation of an NF-κB-like activity in Xenopus Laevis Oocytes" Mol. Cell. Biol., Vol. 13, No. 2, pp. 1290-1295 (1993)						
		B13	Finco, et al., "Inducible phosphorylation of IkBa is not sufficient for its dissociation from NF-kB and is inhibited by protease inhibitors" <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91, pp. 11884-11888 (1994)						
-		B14	Finco and Baldwin, "kB Site-Dependent Induction of Gene Expression by Diverse Inducers of Nuclear Factor kB Requires Raf-1", <i>J. Biol Chem.</i> , Vol. 268, No. 24, pp. 17676-17679 (1993)						
	\ :::	B15	Finco and Baldwin, "Mechanistic Aspect of NF-kB Regulation: The Emerging Role of Phosphorylation and Proteolysis" Immunity, Vol. 3, pp. 263-272 (1995)						
		B16	Francis and Corbin, "Structure and Function of Cyclic Nucleotide-dependent Protein Kinases" <i>Annu. Rev. Physiol.</i> , Vol. 56, pp. 237-72 (1994)						
	Γ.	B17	Ghosh and Baltimore, "Activation Invitro of NF-kB by Phosphorylation of its Inhibitor lkB" Nature, Vol. 344, pp. 678-682 (1990)						
	m	B18	Goldberg, Alfred L., "Functions of the Proteasome: The Lysis at the End of the Tunnel"						

EXAMINER MALLEST	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not cita	

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

OF

3. --

Docket Number 1,03576.166 Application Number

15/8/293

Applicant

Chen, Zhijian H.

Filing Date

Group Art Unit

September 24, 1999

5

1652

10	M	C1	Pathway" Science, Vol. 267, pp. 389-393 (1995)
		C2	Haskill, et al., "Characterization of an Immediate-Early Gene Induced in Adherent Monocytes that Encodes IkB-like Activity" Cell, Vol. 65, pp. 1281-1289 (1991)
		Сз	Henkel, et al., * Rapid Proteolysis of IκB-α is Necessary for Activation of Transcription Factor NF-κB* Nature, Vol. 365, pp. 182-185 (1993)
		C4	Hershko and Heller, "Occurrence of a Polyubiquitin Structure in Ubiquitin-Protein Conjugates" Biochem. Biophys. Res. Commun., Vol. 128, No. 3, pp. 1079-1086 (1985)
		_C5	Hershko and Ciechanover, "The Ubiquitin System for Protein Degradation" Annu. Rev. Biochem., Vol. 61, pp. 761-807 (1992)
		Се	Hibi, et al., "Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain" Genes and Dev., Vol. 7, pp. 2135-2148 (1993)
	ı	C7	Higgins, et al., "Antisense inhibition of the p65 subunit of NF-kB blocks tumorigenicity and causes tumor regression" <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 90, pp. 9901-9905 (1993)
	_`	C8	-Hirano, et al., "MEK Kinase Is Involved in Tumor Necrosis Factor α-Induced NF-κB Activation and Degradation of IκB-α" <i>J. Biol. Chem.</i> , Vol. 217, No. 22, pp. 13234-13238 (1996)
	· ··-	C9	Kumar, A., et al., "Double-Stranded RNA-Dependent Protein Kinase Activates Transcription Factor NF-κB by Posphorylating IκB" <i>Proc. Natl. Acad. Sci. USA</i> Vol. 91, pp. 6288-6292 (1994)
		C10	Kuno, et al., *Identification of an IκB-α - Associated Protein Kinase in a Human Monocytic Cell Line and Determination of its Phosphorylation Sites on IκB-α Biol. Chem. Vol. 270, No. 46, pp. 27914-27919 (1995)
E		C11	Lange-Carter, et al., "A Divergence in the MAP Kinase Regulatory Network Defined by MEK Kinase and Raf" Science, Vol. 260, pp. 315-319 (1993)
		C12	Li and Sedivy "Raf-1 Protein Kinase Activates the NF-kB Transcription Factor By Disassociating the Cytoplasmic NF-kB-lkB complex" <i>Proc Natl Acad Sci USA.</i> , Vol. 90, pp. 9247-9251 (1993)
		C13	Lin, et al., "Activation of NF-kB requires proteolysis of the inhibitor IkB-a: Signal-induced phosphorylation of IkB-a alone does not release active NF-kB" <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 92, pp. 552-556, (1995)
		C14	Lin and Desiderio, "Regulation of V(D)J Recombination Activator Protein RAG-2 by Phosphorylation" Science, Vol. 260; pp. 953-959 (1993)
		C15	Mellits, et al., "Proteolytic degradation of MAD3 (IκBα) and enhanced processing of the NF-κB precursor p105 are obligatory steps in the activation of NF-κB" <i>Nucl. Acid. Res.</i> , Vol. 21, No. 22, pp. 5059-5066 (1993)
9	M	C16	Miyamoto, et al., "Tumor necrosis factor α-induced phosphorylation of lκBα is a signal for its degradation but not dissociation from NF-κB" <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91, pp. 12740-12744 (1994)

EXAMINER D. ///	DATE CONSIDERED
(AND WHAN)	
Mullia	3/4/06
EXAMINER: Initial if citation is considered, whether or not cita	ion is in conformance with MPEP & 609: Draw Line through
citation if not conformance and not considered, Include copy with	next communication to applicant.

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

OF

5

4

Docket Number 103576.166 Application Number

09/460,293

Applicant Chen, Zhijian H.

Filing Date Group Art Unit
September 24, 1999 - 1652

_			
	\mathcal{M}	D1	Nishizawa, M., et al., "Degradation of MOS by the N-terminal Proline-(Pro2)-Dependent Ubiquitin Pathway on Fertilization of Xenopus Eggs: Possible Significance of Natural Selection for Pro2 in MOS" EMBO J., Vol. 12, No. 10, pp. 4021-4027 (1993)
	7	D2	Palombella, et al., "The Ubiquitin-Proteasome Pathway is Required For Processing the NF- κB1 Precursor Protein and the Activation of NF-κB" Cell, Vol. 78, pp. 773-785 (1994)
		.D3	Pawlak, et al., "Characterization of a Large Population of mRNAs From Human Testis" Genomics, Vol. 26, pp. 151-158 (1995)
$\cdot \lceil$		D4	Pickart and Rose, "Functional Heterogeneity of Ubiquitin Carrier Proteins" J. Biol. Chem., Vol. 260, No. 3, pp. 1573-1581 (1985)
		D 5	Read, et al., "The Proteasome Pathway Is Required for Cytokine-Induced Endothelial- Leukocyte Adhesion Molecule Expression" <i>Immunity</i> , Vol. 2, pp. 493-506 (1995)
$\cdot [$		D6	Rodriguez, M.S., et al, "Inducible Degradation of IkBa In Vitro and In Vivo Requires the Acidic C-Terminal Domain of the Protein" Mol. Cell. Biol., Vol. 15(5), pp. 2413-2419 (1995)
-		D7	Scherer, et al., "Signal-Induced Degradation of IκB-α requires site-specific Ubiquitination" Natl. Acad. Sci. USA., Vol. 92, pp. 11259-11263 (1995)
		D8	Schreck, et al., "Reactive Oxygen Intermediates as Apparently Widely Used Messengers in the Activation of the NF-kB Transcription Factor and HIV-1" EMBO J., Vol. 10 No. 8, pp. 2247-2258 (1991)
		D9	Schutze, et al., "TNF Activates NF-kappa B by Phosphatidylcholine-Specific Phospholipase C-Induced "Acidic" Sphingomyelin Breakdown" Cell, Vol. 71 pp.765 -777
		D10	Siebenlist, et al., "Structure, Regulation and Function of NF-kB" Annu. Rev. Cell Biol., Vol. 10, pp. 405-455 (1994)
		D11	Sun, et al., "NF-κB Controls Expression of Inhibitor IκB-α: Evidence For An Inducible Autoregulatory Pathway", Science, Vol. 259, pp. 1912-1915 (1993)
Γ		D12	Thanos and Maniatis, "NF-kB: A Lesson in Family Values" Cell, Vol. 80, pp. 529-532 (1995)
		D13	Thévenin, et al., "Induction of Nuclear Factor-kB and the Human Immunodeficiency Virus Long Terminal Repeat by Okadaic Acid, A Specific Inhibitor of Phosphatases 1 and 2A" New Biol., Vol. 2, pp. 793-800 (1990)
		D14	Traenckner et al., "A Proteasome Inhibitor Prevents Activation of KF-κB and Stabilizes a Newly Phosphorylated Form of IκB-α That is Still Bound to NF-κB" <i>EMBO J.</i> , Vol. 13, pp.5433-5441 (1994)
		 D15	Traenckner, E.BM.,et al, "Phosphorylatin of Human IκB-α on Serines 32 and 36 Controls IκB-α Protealysis and NF-κB Activation in Response to Diverse Stimuli" " <i>EMBO J.</i> , Vol. 14, No. 12, pp. 2876-2883 (1995)
	7	D16	Verma, et al., "Rel/NF-kB/lkB Family: Intimate-Tales of Association and Disassociation" Genes and Dev., Vol. 9 pp. 2723-2735 (1995)
		D17	Wasserman, "A Conserved Signal Transduction Pathway Regulating the Activity of the Rel- Like Proteins Dorsal and NF-kB" <i>Mol. Biol. Cell.</i> , Vol. 4, pp. 767-771 (1993)

EXAMINER / //	DATE CONSIDERED/
Mullim	\$ 19/01
	//////
EXAMINER: Initial if citation is considered, whether or not citati	on is in conformance with MPEP § 609: Draw Line through
citation if not conformance and not considered. Include conv. with a	

Docket Number Application Number Subl. For, PTO-1449 Q9/460,293 103576.166 INFORMATION DISCLOSURE Applicant IN AN APPLICATION Chen, Zhijian H. (Use several sheets if necessary) **Group Art Unit** Filing Date _Sheet - . 5 OF 5 1652 September 24, 1999

0/	E1	Whiteside, et al., "N- and C- Terminal Sequences Control Degradation of MAD3/lk-B_n_in. Response to Inducers of NF-kB Activity" Mol. Cell. Biol., Vol. 15, No. 10, pp. 5339-5345 (1995)
9	E2	Yaglom, et al., "p34Cdc28-Mediated Control of Cln3 Cyclin Degradation" Mol. Cell. Biol., Vol. 15, No. 2, pp. 731-741 (1995)
	E3	Yang, et al., "Deficient signaling in mice devoid of double-stranded RNA-dependent Protein kinase" EMBO J., Vol. 14, No. 24, pp. 6095-6106 (1995)
	E4	EMBL Database entry Hs369288, Accession Number N56369, from International Search Report, International Application No. PCT/US97/04195
(%)	Es	EMBL Database entry Hs2038; Accession Number T19203, from International Search Report, International Application No. PCT/US97/04195
$\overline{}$		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1

anthony w. sutton - z\legal\103576.166\1449.doc

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609; Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 103576.166 Application Number 09/406,293

Applicant Chen

Filing Date

Group Art-Unit

Sheet 1 OF 1

September 24, 1999>

1652

			U.:	S. Patent Docume	ents		
	AMINER WITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
11/1		5,972,674	10/26/99	Mercurio, et al.	435	194	·
	48	6,258,579	7/10/01	Mercurio, et al.	435	194	
	1 NI	6,268,194	7/31/01	Karin, et al.	435	194	
$\Box \mathcal{A}$	1177	6,242,253	6/5/01	Karin, et al.	435	325	

		Fore	ign Patent Docur	nents			
EXAMINER INITIAL /	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS	LATION
1 1 1				05.00	500000	YES	NO
	98/08955	3/5/98	wo				
AVI VI	98/37228	8/27/98	wo				

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
Lee_et al. "Activation of the IκΒα Kinase Complex by MEKK1, a Kinase of the JNK Pathway"
Cell, Vol. 88, pp. 213-222 (1997)

EXAMINER

DATE CONSIDERED

PTO/SB/08B (10-96)
Approve use through 10/31/99. OMB 0654-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known			
INFO	RMATIC	ON DIS	SCLOSURE	Application Number	10/052,005 18/8/0 -16		
	STATEMENT BY APPLICANT			Filing Date	January 17, 2002		
SIA	I CIVICIA I	BIA	PPLICANI -	First Named Inventor	Chen, Zhijian J.		
		•		Group Art Unit	1652		
0 .	(USB BS ME	ny sheets as	necessary)	Examiner Name	Patterson, Charles, L., Jr.		
Sheet		of	5	Attorney Docket Number	MPI96-031CP1DV1CPACN1M		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Cusania a c	0.11	Include the name of the author (in CAPTIAL LETTERS) title of the article (under control to the c	_
Examiner Initials*	Cite No. ¹	city and-or country where published	·T²
	A3	Amason, I. and Ellison, M.J., "Stress resistance in Saccharomyces corpyicing in attenute and the	
	Alt	with assembly of a novel type of multiubiquitin chain", Molecular and Cell Biology, Volume 14, Number 12, pages 7876-7883 (1994)	
F	A5	Auphan, N., et al., "Immunosuppression by Glucocorticoids: Inhibition of NF-kB Activity Through Induction of IkB Synthesis" Science, Volume 270, pages 286-290 (1995)	
	11		
<u></u>	A6	Baeuerle, P. and Henkel, T., "Function and Activation of NF-kB in the Immune System", Annual Review of Immunology, Volume 12, pages 141-179 (1994)	
	10		
	ATT	Blank, J., et al. "Molecular Cloning of Mitogon activated Protein (CDIC Village)	
CA)	M	Blank, J., et al., "Molecular Cloning of Mitogen-activated Protein/ERK Kinase Kinases (MEKK) 2 and 3", The Journal of Biological Chemistry, Volume 271, Number 10, pages 5361-5368 (1996)	
77	BI	Chen, P., et al., "Multipile Ubiquitin-Conjugating Enzymes Participate in the In Vivo Degradation of	
$\overline{}$	AL	the Yeast MATo2 Repressor", Cell, Volume 74, pages 357-369 (1993)	
$\overline{}$	184	Chen 7 of al "A 25 Kiloday - Uni in a	
	AM	Chen, Z., et al., "A 25-Kilodalton Ubiquitin Carrier Protein (E2) Catalyzes Multiubiquitin Chain Synthesis via Lysine 48 of Ubiquitin", The Journal of Biological Chemistry, Volume 265, Number 35, pages 21835-21842 (1990)	7
	B5	Choi, K., et al., "Ste5 Tethers Multiple Protein Kinases in the MAP Kinase Cascade Required for Mating in S. cerevisiae", Cell, Volume 78, pages 499-512 (1994)	
-			
	AO	Derijard, B., et al., "Independent Human MAP Kinase Signal Transduction Pathways Defined by MEK and MKK Isoforms" Science, Volume 267, pages 682-685 (1995)	
	[[
/	88 M7	Derijard, B., et al., "JNK1: A Protein Kinase Stimulated by UV Light and Ha-RAS That Binds and Phosphorylates the c-Jun Activation Domain", Cell, Volume 76, pages 1025-1037 (1994)	
/	71/ L	DiDonato I et al "Dhasabardelia (U.C. D	
	😽 '	DiDonato, J., et al., "Phosphorylation of IkBa Precedes but Is Not Sufficient for Its Dissociation from NF-kB", Molecular and Cellular Biology, Volume 15, Number 3, pages 1302-1311 (1995)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here is English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

ssistant Commissione

		PTO/SB/	08B (10-96
Approv.	्र [}] use	through 10/31/99. OM	3 0654 003

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	e for form 1449	B/PTO		Complete if Known			
INFO	DRMAT	ION DIS	CLOSURE	Application Number	10/052005 [0/8/0/19]		
STA	STATEMENT BY APPLICANT			Filing Date First Named Inventor	January 17, 2002 / Chen, Zhijian J.		
				Group Art Unit	1652		
	use es	many sheets as	necessary)	Examiner Name	Patterson, Charles L., Jr		
Sheet	2	of	5	Attorney Docket Number	MPI96-031CP1DV1CPACN1M		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner nitials*	Cite No.1	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	B13	Fince, T., et al., "Inducible phosphoriation of IkBa is not sufficient for its dissociation from NE kB and	1
	K	is inhibited by protease inhibitors. Proceedings of the National Academy of Sciences USA, Volume 91, pages 11884-11888 (1994)	-
	A.	Finco, T., et al., "Mechanistic Aspects of NF-kB Regulation: The Emerging Role of Phosphorylation and Proteolysis", Immunity, Volume 3, pages 263-272 (1995)	
-	A A	Francis, S. and Corbin, D., Structure and Function of Cyclic Nucleotide Dependent Protein Kinases* Annual Review of Physiology, Volume 56, pages 237-272 (1994)	
	AU	Goldberg, A., "Functions of the Proteasome: The Lysis at the End of the Tunnel", Science, Volume 260, pages 522-523 (1995)	
	Al Al	Gupta, S., et al., "Transcription Factor ATF2 Regulation by the JNK Signal Transduction Pathway", Science, Volume 267, pages 389-393 (1995)	
	W.	Haskill, S., et al., Characterization of an Immediate-Early Gene Induced in Adherent Monocytes That Encodes IkB-like Activity, Cell, Volume 65, pages 1281-1289 (1991)	
	es X	Hershko, A. and Heller, H. "Occurrence of a Polyubiquitin Structure in Ubiquitin-Protein Conjugates", Biochemical and Biophysical Research Communications, Volume 128, Number 3, pages 1079-1086 (1985)	
	₩ M	Hibi, M., et al., "Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain" Genes and Development, Volume 7, pages 2135-2148 (1993)	
	O AZ	Higgins, K., et al., "Antisense inhibition of the p65 subunit of NF-kB blocks tumorigenicity and causes tumor regression", Proceedings of the National Academy of Sciences USA, Volume 90, pages 9901-9905 (1993)	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

both of Page

¹Unique citation design number. ²Applicant is to place a check mark here is English language Translation is attached.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	for form 1449B/F	то		Com	plete if Known
			CLOSURE	Application Number Filing Date	-10/052005 6/1/0 /// 3 January 17, 2002
SIAI	EMENI	BY A	PLICANT	First Named Inventor	Chen, Zhijian J.
ļ				Group Art Unit	1652
-	· (use as mar	iy-sheets as	necessary) —	Examiner Name	Patterson, Charles L., Jr.
Sheet	3	of	5	Attorney Docket Number	MPI96-031CP1DV1CPACN1M

	·	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	- ~
Examiner	Cite	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item	Г
Initials*	No.1	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T
	158	Hirano, M., et al., "MEK Kinase is involved in Tumor Necrosis Factor a Induced NE LD Assistant	╁
\neg .	12/	and Degradation of IkB-o*, The Journal of Biological Chemistry, Volume 217, Number 22, pages	╁
3	M	13234-13238 (1996)	
	SET	Lange-Carter, C.A., et al., 'A Divergence in the MAP Kinase Regulatory Network Defined by MEK	╁
	100	Kinase and Raff, Science, Volume 260, pages 315-319 (1993)	
	10/		١
	·045-	-Lin, YC., et al., "Activation of NF-kB requires proteolysis of the inhibitor IkB-a: Signal-induced	T
	80	phosphorylation of lkB- α alone does not release active NF-kB*, Proceedings of the National Academy of Sciences USA, Volume 92, pages 552-556 (1995)	
	æ13	-Mellits; K.H., et al., "Proteolytic degradation of MAD3 (IKB a) and enhanced processing of the NF-kB	╁
	Bb	precursor p105 are obligatory steps in the activation of NF-kB*, Nucleic Acids Research, Volume 21, Number 22, pages 5059-5068 (1993)	
	<i>8</i> 46	Miyomoto, S., et al., Tumer pecrosis factor α-induced phosphorylation of IkB α is a signal for its	╀
•	BE	degradation but not dissociation from NF-kB", Proceedings of the National Academy of Sciences USA, Volume 91, pages 12740-12744 (1994)	
	×96>	Read, M.A., et al., "The Proteasome Pathway is Required for Cytokine-Induced_Endothelial-	╁
	DY.	Leukocyte Adhesion Molecule Expression, Immunity, Volume 2, pages 493-506 (1995)	
	BF		
<i>"</i>	23 10	Siebenlist, U., et al., "Structure, Regulation and Function of NF-kB", Annual Review of Cell Biology.	H
	101	Volume 10, pages 405-455 (1994)	l
			l
	4949/	Thanos, D. and Maniatis, T., "NF-kB: A Lesson in Family Values", Cell, Volume 80, pages 529-532	├
	MIL	(1995)	
	110		1
	≥ 2913	Thomasia Country and a second	
	11	Thevenin, C., et al., "Induction of Nuclear Factor-kB and the Human Immunodefiency Virus Long	Π
	81	Terminal Repeat by Okadalc Acid, a Specific Inhibitor of Phosphatases 1 and 2A", New Biologist, Volume 2, Number 9, pages 793-800 (1990)	
		N. M. /	L
	C	1\JUUBN 3 8 po	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here is English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

in they

Approve. .or use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number.

Complete if Known Substitute for form 1449B/PTO INFORMATION DISCLOSURE **Application Number** 10/052005 January 17, 2002 Filing Date STATEMENT BY APPLICANT **First Named Inventor** Chen, Zhijian J. Group Art Unit 1652 (use as many sheets as necessary) **Examiner Name** Patterson, Charles L., Jr. Sheet **Attomey Docket Number** MPI96-031CP1DV1CPACN1M

	T	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS -		
Examiner Initials*	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of to (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), put city and-or country where published.			
	215	Traenckner, E.B., et al., *Phosphorylatin of Human IkB-α on Serines 32 and 36 Controls IkB-α Protealysis and NF-kB Activation in Response to Diverse Stimuli*, The EMBO Journal, Volume 14, Number 12, pages 2876-2883 (1995)		
	HH.	Yang, YL., et al., "Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase", The EMBO Journal, Volume 14, Number 24, pages 6095-6106 (1995)		
M	5ª	Xu, S., et al., "Cloning of rat MEK kinase 1 cDNA reveals an endogenous membrane-associated 195-kDa protein with a large regulatory domain", Proceedings of the National Academy of Sciences USA, Volume 93, pages 5291-5295 (1996)		
	#2 BM	Khoshnan, A., et al., "The Physical Association of Protein Kinase C0 with a Lipid Raft-Associated Inhibitor of kB Factor Kinase (IKK) Complex Plays a Role in the Activation of the NF-kB Cascade by TCR and CD28 ¹ ", The Journal of Immunology, Volume 165, pages 6933-6940 (2000)		
	BN	DiDonato, J.A., et al., *A Cytokine-responsive lkB kinase that Activates the Transcription Factor NF-kB*, Nature, Volume 388, pages 548-554 (August 1997)		
	BO	Miller, B.S. and Zandi, E., "Complete Reconstitution of Human IkB Kinase (IKK) Complex in Yeast", The Journal of Biological Chemistry, Volume 276, Number 39, pages 36320-36326 (September 28, 2001)		
	BP.	Fu, DX., et al., "Human T-lymphotropic Virus Type I Tax Activates I-kB Kinase by Inhibiting I-kB Kinase-associated Serine/Threonine Protein Phosphatase 2A", The Journal of Biological Chemistry, Volume 278, Number 3, pages 1487-1493 (January 17, 2003)		
	70	Storz, P. and Toker, A., "Protein kinase D mediates a stress-induced NF-kB Activation and Survival Pathway", The EMBO Journal, Volume 22, Number 1, pages 109-120 (2003)		
	界	Yang, J., et al., "The Essential Role of MEKK3 in TNF-induced NF-kB Activation", Nature Immunology, Volume 2, Number 7, pages 620-624 (July 2000)		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here is English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

F10/58/088 (10-88)

Approve For use through 10/31/99. OMB 0654-0031

Patent and Trademar. ce: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	e for form 1449	в/РТО		Com	plete if Known
INFC	RMATI	ON DIS	SCLOSURE	Application Number Filing Date	_10/052905
STA	TEMEN	T BY A	PPLICANT	First Named Inventor	Chen, Zhijian J.
ł			··············	Givop Ari Unii	1652
	(use as n	nany sheets a	s necessary)	Examiner Name	Patterson, Charles L., Jr.
Sheet	5	ol	5	Attorney Docket Number	MPI96-031CP1DV1CPACN1M

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.'	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T'
M	\$ 5	Zhao, Q. and Lee, F.S., "Mitogen-activated Protein Kinase/ERK Kinase Kinases 2 and 3 Activate Nuclear Factor-kB through IkB Kinase-a and IkB Kinase-B", The Journal of Biological Chemistry, Volume 274, Number 13, pages 8355-8358 (March 26, 1999)	
	7	Tojima, Y., et al., "NAK is an IkB kinase-activating kinase", Nature, Volume 404, pages 778-782 (April 13, 2000)	
	### DU	Wang, C., et al., "TAK1 is a Ubiquitin-dependent kinase of MKK and IKK", Nature, Volume 412, pages 346-351 (July 19, 2001)	
	BU	Regnier, C.H., et al., "Identification and Characterization of an IkB Kinase", Cell, Volume 90, pages / 373-383 (July 25, 1997)	
M	BU	Connelly, M.A. and Marcu, K.B., "CHUK, A New Member of the Helix-loop-helix and Leucine Zipper Families of Interacting Proteins, Contains a Serine-Threonine Kinase Catalytic Domain", Cellular and /Molecular Biology Research, Volume 41, Number 6, pages 537-549 (1995)	

Examiner Signature	Malleyn.	 Date Considered	5/9/06	
	- 0 W - 0 0 2 / V		10/0/	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{&#}x27;Unique citation design number. ²Applicant is to place a check mark here is English language Translation is attached.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	for form 1449A/PT	0		Сотр	olete if Known
			CLOSURE	Application Number Filing Date	10/052,005 / 8 / 8 / 9 / 9 / 9 / 9 / 9 / 9 / 9 / 9
S.I.A.	FFWFNI	3Y AF	PPLICANT	First Named Inventor	Chen, Zhijian J.
				Group Art Unit	1652
	(use as many	sheets as	necessary)	Examiner Name	Patterson, Charles L., Jr.
Sheet	1	of	1	Attorney Docket Number	MPI96-031CP1DV1CPACN1M

				U.S. PATENT DOCUME	:N15	
Examiner Initials*	Cite No. ¹		Document ind Code ² if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited-Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	S1	5,830,756		Chiron Corporation/University of North Carolina	11/03/1998	
W	S2	6,576,437		Signal Pharmaceuticals, Inc.	06/10/2003	
			-			·
	-		<u> </u>			
						·
			•			
			-		,	
						<u>_</u>

				FORE	IGN PATENT DOCI	UMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document			Name of Patentee	Date of Publication of	Pages, Columns, Lines, Where	
		Office ³	Number ⁴	Kind Code ⁵ (if known)	or Applicant of Cited Document	Cited Document (MM-DD-YYYY)	Relevant Passages or Relevant Figures Appear	T⁵
				· .				

			<u> </u>			
Examiner	1 M 1	GAIN	Date		-/	/
Signature	1 / · / 411 // // 91	MN	Considered		10	2/06
<u> </u>		W/ V	Considered	/	4	100

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁸Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) Inside this box -> +

PTO/SB/08B (10-98) Approved for use through 10/31/99. OMB 0854-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known			
INIEOE	DIAATION	DISCL	OSLIBE	Application Number	10/810,793		
INFORMATION DISCLOSURE				Filing Date	March 26, 2004		
STATEMENT BY APPLICANT		First Named Inventor	Chen, Zhijian J.				
•				Group Art Unit	1652		
(use as many sheets as necessary)			sary)	Examiner Name	Patterson, Charles L., Jr.		
Sheet	1	of	1	Attorney Docket Number	MPI96-031CP1DV1CPACN2M		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	7 2
M	F13	Tamaoki, T., et al., "Staurosporine, a potent inhibitor of phospholipida/Ca++ dependent protein kinase," <i>Biochemical and Biophysical Research Communications</i> , Vol. 135, Issue 2 (March 1986) pp 397-402	
/	F14	Kase, H., et al., "K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases," <i>Biochemical and Biophysical Research Communications</i> , Vol. 142, Issue 2 (January 1987) pp 436-440	
CM	F15	Segel, I.H., Enzyme Kinetics (1975) pp 89-96	
		·	-
<u> </u>			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PAGE 11/25 * RCVD AT 3/30/2006 10:57:05 AM [Eastern Standard Time] * SVR:USPTO-EFXRF-2/15 * DNIS;2738300 * CSID:617 551 8820 * DURATION (mm-ss):10-36

¹Unique citation design number. ²Applicant is to place a check mark here is English language Translation is attached.